ClinicalTrials.gg
RecruitingNCT07317297Updated Jan 16, 2026

Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease

An interventional study of Extracorporeal Shockwave Therapy and control in Peyronie Disease, sponsored by Uskudar University. Recruiting at 1 site in Azerbaijan. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Uskudar University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.

Read the detailed description

The study is designed as a single-center, prospective clinical trial. Participants will be selected from among patients who present to the clinic and are diagnosed with stable stage Peyronie's disease. All participants who meet the eligibility criteria and provide written consent will undergo a standard Extracorporeal Shockwave Therapy protocol. All participants will be evaluated before and after treatment using the International Erectile Function Index-5 and the Quality of Life Questionnaire short form. The results will be statistically analyzed and interpreted.

02

Conditions studied

  • Peyronie Disease

Browse trials for

03

In context

Penile Induration

48 studies on the registry are indexed under Penile Induration; 10 are open to participants now.

This study's planned enrollment of 50 is above the median of 40 across 40 interventional studies indexed under Penile Induration.

Browse Penile Induration studies →

Lead sponsor

Uskudar University is the lead sponsor of 173 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male individuals aged 18-65 years.
  • Having been diagnosed with Peyronie's Disease that has been stable (without increasing pain and curvature) for at least 6 months.
  • Presence of palpable penile plaque.

Exclusion criteria

Exclusion Criteria:

  • Acute inflammatory stage (painful, progressive)
  • Having previously undergone surgery, needle therapy (e.g., Xiaflex), or Extracorporeal Shockwave Therapy for peyronie's disease.
  • Uncontrolled diabetes, severe coagulopathy, or receiving anticoagulant therapy.
  • History of penile cancer.
  • Severe erectile dysfunction.
  • Patients who are considered unable to comply with the study protocol or who cannot attend follow-up visits.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    control

    patients receiving normal routine pharmacological treatment without any special intervention

    Other: control

  • Experimental
    Extracorporeal Shockwave Therapy

    Patients receiving Extracorporeal Shockwave Therapy treatment

    Other: Extracorporeal Shockwave Therapy

Interventions

  • OtherExtracorporeal Shockwave Therapy

    Extracorporeal Shockwave Therapy will follow a standard protocol. The treatment is planned as a total of 8 sessions (3000 pulses per session, 2.5 bar pressure, 15 Hz frequency) twice a week using a radial shockwave device. Focusing will be done on the penile shaft via gel according to the plaque localization, and shock waves will be applied to the plaque area.

  • Othercontrol

    patients receiving normal routine pharmacological treatment without any special intervention

06

What researchers measure

Primary outcomes

  1. Erectile function

    The International Index of Erectile Function is recorded as a total score. It is measured by a self-reported questionnaire with 5 domains, with each domain consisting of 5 options. The score ranges from 5 to 25, with 5 being the lowest score (severe erectile dysfunction) and 25 being the best score (maximal erection)

    Time frame: 5 weeks

  2. Short Form-36

    Short Form-36 Health Survey is a non-disease-specific instrument consisting of 36 items used to assess health-related quality of life. It includes eight subscales covering physical and mental health domains. Each subscale is scored from 0 to 100, with higher scores indicating better health status, while one item assessing health change is not included in subscale scoring. A high score indicates a higher quality of life.

    Time frame: 5 weeks

07

Study locations

1 of 1 sites recruiting
  • Koreya Serq Tebabeti
    Baku, Azerbaijan
    Recruiting
08

References and documents

Publications

  • Ergun M, Sagir S. Low-Intensity Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma: Effective Combination Treatment of Chronic-Phase Peyronie's Disease. Arch Esp Urol. 2025 Mar;78(2):164-169. doi: 10.56434/j.arch.esp.urol.20257802.23. PubMed 40191859 ↗
  • Porst H. Review of the Current Status of Low Intensity Extracorporeal Shockwave Therapy (Li-ESWT) in Erectile Dysfunction (ED), Peyronie's Disease (PD), and Sexual Rehabilitation After Radical Prostatectomy With Special Focus on Technical Aspects of the Different Marketed ESWT Devices Including Personal Experiences in 350 Patients. Sex Med Rev. 2021 Jan;9(1):93-122. doi: 10.1016/j.sxmr.2020.01.006. Epub 2020 Jun 2. PubMed 32499189 ↗
  • Rosenberg JE, Ergun O, Hwang EC, Risk MC, Jung JH, Edwards ME, Blair Y, Dahm P. Non-surgical therapies for Peyronie's disease. Cochrane Database Syst Rev. 2023 Jul 17;7(7):CD012206. doi: 10.1002/14651858.CD012206.pub2. PubMed 37490423 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Feb 2026, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 5, 2026
StartActual
Jan 10, 2026
Primary completionEst.
Feb 15, 2026
CompletionEst.
Mar 30, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07317297
Lead sponsor
Uskudar University
Responsible party
Doç.Dr.Ömer Şevgin (Assoc.Prof.Dr., Uskudar University) — Principal investigator
First posted
Jan 5, 2026
Start date
Jan 10, 2026
Primary completion
Feb 15, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Ömer ŞEVGİN
Contact
omer.sevgin@uskudar.edu.tr
+905069787535
Aziz Azizov
study chair · Uskudar University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion